Skip to main content
Erschienen in: Der Urologe 12/2017

17.10.2017 | Allgemeine Diagnostik | Leitthema

Überaktive Blase – wann welche Therapie?

verfasst von: Prof. J. Pannek

Erschienen in: Die Urologie | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die OAB (überaktive Blase/„overactive bladder“) stellt einen klinischen Symptomenkomplex dar. Die initiale Therapie sollte daher auf den klinischen Symptomen und einer Basisdiagnostik beruhen. Bei der Wahl der Ersttherapie spielt die Patientenpräferenz eine entscheidende Rolle. Neben verhaltenstherapeutischen Ansätzen stehen Elektrostimulation und medikamentöse Therapien zur Verfügung. Bei nicht ausreichendem Ansprechen sollte vor einer Therapieeskalation mit minimal-invasiven Behandlungen, wie Onabotulinumtoxin-Injektionen in den Detrusor oder sakrale Neuromodulation, eine erweiterte Diagnostik erfolgen. Chirurgische Maßnahmen wie z. B. Blasenaugmentation sind nur in Ausnahmefällen erforderlich.
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed
2.
Zurück zum Zitat Azuri J, Kafri R, Ziv-Baran T, Stav K (2017) Outcomes of different protocols of pelvic floor physical therapy and anti-cholinergics in women with wet over-active bladder: a 4‑year follow-up. Neurourol Urodyn 36:755–758CrossRefPubMed Azuri J, Kafri R, Ziv-Baran T, Stav K (2017) Outcomes of different protocols of pelvic floor physical therapy and anti-cholinergics in women with wet over-active bladder: a 4‑year follow-up. Neurourol Urodyn 36:755–758CrossRefPubMed
3.
Zurück zum Zitat Biers SM, Venn SN, Greenwell TJ (2012) The past, present and future of augmentation cystoplasty. BJU Int 109:1280–1293CrossRefPubMed Biers SM, Venn SN, Greenwell TJ (2012) The past, present and future of augmentation cystoplasty. BJU Int 109:1280–1293CrossRefPubMed
4.
Zurück zum Zitat Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, Varner RE, Lloyd LK (2002) Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 288:2293–2299CrossRefPubMed Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, Varner RE, Lloyd LK (2002) Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 288:2293–2299CrossRefPubMed
5.
Zurück zum Zitat Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, Colli J, Vaughan CP, Redden DT (2011) Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) trial. J Am Geriatr Soc 59:2209–2216CrossRefPubMed Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, Colli J, Vaughan CP, Redden DT (2011) Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) trial. J Am Geriatr Soc 59:2209–2216CrossRefPubMed
6.
Zurück zum Zitat Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM (2012) Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 62:1040–1060CrossRefPubMed Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM (2012) Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 62:1040–1060CrossRefPubMed
7.
Zurück zum Zitat Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M (2001) Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology 47:72–76CrossRefPubMed Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M (2001) Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology 47:72–76CrossRefPubMed
8.
Zurück zum Zitat Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, Chen B, Lv J (2017) Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology 100:59–64CrossRefPubMed Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, Chen B, Lv J (2017) Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology 100:59–64CrossRefPubMed
9.
Zurück zum Zitat Cheng CL, Li JR, Lin CH, de Groat WC (2016) Positive association of female overactive bladder symptoms and estrogen deprivation: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore) 95:e4107CrossRef Cheng CL, Li JR, Lin CH, de Groat WC (2016) Positive association of female overactive bladder symptoms and estrogen deprivation: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore) 95:e4107CrossRef
11.
Zurück zum Zitat Cui Y, Zong H, Yang C, Yan H, Zhang Y (2014) The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 46:275–284CrossRefPubMed Cui Y, Zong H, Yang C, Yan H, Zhang Y (2014) The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 46:275–284CrossRefPubMed
12.
13.
Zurück zum Zitat Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D, Chapple CR (2017) Comparative assessment of efficacy of onabotulinumtoxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. https://doi.org/10.1111/bju.13945 Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D, Chapple CR (2017) Comparative assessment of efficacy of onabotulinumtoxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. https://​doi.​org/​10.​1111/​bju.​13945
14.
Zurück zum Zitat Eldred-Evans D, Sahai A (2017) Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 9:3–10CrossRefPubMed Eldred-Evans D, Sahai A (2017) Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 9:3–10CrossRefPubMed
15.
Zurück zum Zitat Forde JC, Davila JL, Marks BK, Epstein M, Tsui JF, Weiss JP, Blaivas JG (2017) Urogynecological conditions associated with overactive bladder symptoms in women. Can Urol Assoc J 11:E83–E87CrossRefPubMedPubMedCentral Forde JC, Davila JL, Marks BK, Epstein M, Tsui JF, Weiss JP, Blaivas JG (2017) Urogynecological conditions associated with overactive bladder symptoms in women. Can Urol Assoc J 11:E83–E87CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, MacDiarmid S, Drake MJ, Devlin N (2017) Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial. Patient. https://doi.org/10.1007/s40271-017-0262-8 PubMed Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, MacDiarmid S, Drake MJ, Devlin N (2017) Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial. Patient. https://​doi.​org/​10.​1007/​s40271-017-0262-8 PubMed
17.
Zurück zum Zitat Homma Y (2008) Lower urinary tract symptomatology: its definition and confusion. Int J Urol 15:35–43CrossRefPubMed Homma Y (2008) Lower urinary tract symptomatology: its definition and confusion. Int J Urol 15:35–43CrossRefPubMed
18.
Zurück zum Zitat Kaufmann A, Kirschner-Hermanns R (2016) Therapie der weiblichen OAB. Aktuelle Urol 47:305–309CrossRefPubMed Kaufmann A, Kirschner-Hermanns R (2016) Therapie der weiblichen OAB. Aktuelle Urol 47:305–309CrossRefPubMed
19.
Zurück zum Zitat Kim A, Lee KS, Kim TB, Kim HJ, Yoo ES, Yun JH, Kim DY, Jung SG, Lee JT, Kim JM, Oh CK, Shin JH, Jeon SH, Lee SH, Han CH, Lee DH, Cho HJ, Choo MS (2017) Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment. Investig Clin Urol 58:42–47CrossRefPubMedPubMedCentral Kim A, Lee KS, Kim TB, Kim HJ, Yoo ES, Yun JH, Kim DY, Jung SG, Lee JT, Kim JM, Oh CK, Shin JH, Jeon SH, Lee SH, Han CH, Lee DH, Cho HJ, Choo MS (2017) Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment. Investig Clin Urol 58:42–47CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Madhu C, Enki D, Drake MJ, Hashim H (2015) The functional effects of cigarette smoking in women on the lower urinary tract. Urol Int 95:478–482CrossRefPubMed Madhu C, Enki D, Drake MJ, Hashim H (2015) The functional effects of cigarette smoking in women on the lower urinary tract. Urol Int 95:478–482CrossRefPubMed
22.
Zurück zum Zitat Marcelissen TA, Rahnama’i MS, Snijkers A, Schurch B, De Vries P (2017) Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol 35:307–311CrossRefPubMed Marcelissen TA, Rahnama’i MS, Snijkers A, Schurch B, De Vries P (2017) Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol 35:307–311CrossRefPubMed
23.
Zurück zum Zitat Pannek J, Janek S, Noldus J (2010) Neurogene oder idiopathische Detrusorüberaktivität nach erfolgloser antimuskarinerger Therapie. Klinische Wertigkeit der externen temporären Elektrostimulation. Urologe A 49:530–535CrossRefPubMed Pannek J, Janek S, Noldus J (2010) Neurogene oder idiopathische Detrusorüberaktivität nach erfolgloser antimuskarinerger Therapie. Klinische Wertigkeit der externen temporären Elektrostimulation. Urologe A 49:530–535CrossRefPubMed
24.
Zurück zum Zitat Robinson D, Hanna-Mitchell A, Rantell A, Thiagamoorthy G, Cardozo L (2017) Are we justified in suggesting change to caffeine, alcohol, and carbonated drink intake in lower urinary tract disease? Report from the ICI-RS 2015. Neurourol Urodyn 36:876–881CrossRefPubMed Robinson D, Hanna-Mitchell A, Rantell A, Thiagamoorthy G, Cardozo L (2017) Are we justified in suggesting change to caffeine, alcohol, and carbonated drink intake in lower urinary tract disease? Report from the ICI-RS 2015. Neurourol Urodyn 36:876–881CrossRefPubMed
25.
Zurück zum Zitat Rovner ES, Raymond K, Andruczyk E, Juul KV (2017) Low-dose Desmopressin and Tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms. https://doi.org/10.1111/luts.12169 PubMed Rovner ES, Raymond K, Andruczyk E, Juul KV (2017) Low-dose Desmopressin and Tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms. https://​doi.​org/​10.​1111/​luts.​12169 PubMed
26.
Zurück zum Zitat Shafik A, Shafik IA (2003) Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol 20:374–377PubMed Shafik A, Shafik IA (2003) Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol 20:374–377PubMed
27.
Zurück zum Zitat Shin JH, Kim A, Choo MS (2017) Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investig Clin Urol 58:261–266CrossRefPubMedPubMedCentral Shin JH, Kim A, Choo MS (2017) Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investig Clin Urol 58:261–266CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Zylstra S, Kan F, Berg KC (2017) Five year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. J Urol 5347(17):77099–77091. https://doi.org/10.1016/j.juro.2017.07.010 Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Zylstra S, Kan F, Berg KC (2017) Five year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. J Urol 5347(17):77099–77091. https://​doi.​org/​10.​1016/​j.​juro.​2017.​07.​010
29.
Zurück zum Zitat Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR (2017) A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. https://doi.org/10.1007/s00192-017-3377-5 PubMedPubMedCentral Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR (2017) A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. https://​doi.​org/​10.​1007/​s00192-017-3377-5 PubMedPubMedCentral
30.
Zurück zum Zitat Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL (2016) Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev 12:CD10098PubMed Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL (2016) Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev 12:CD10098PubMed
31.
Zurück zum Zitat Sukhu T, Kennelly MJ, Kurpad R (2016) Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol 8:193–199PubMedPubMedCentral Sukhu T, Kennelly MJ, Kurpad R (2016) Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol 8:193–199PubMedPubMedCentral
32.
Zurück zum Zitat Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ (2017) Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol 197:982–990CrossRefPubMed Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ (2017) Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol 197:982–990CrossRefPubMed
33.
Zurück zum Zitat Vijverberg MA, Stortelder E, de Kort LM, Kok ET, de Jong TP (2011) Long-term follow-up of incontinence and urge complaints after intensive urotherapy in childhood (75 patients followed up for 16.2–21.8 years). Urology 78:1391–1396CrossRefPubMed Vijverberg MA, Stortelder E, de Kort LM, Kok ET, de Jong TP (2011) Long-term follow-up of incontinence and urge complaints after intensive urotherapy in childhood (75 patients followed up for 16.2–21.8 years). Urology 78:1391–1396CrossRefPubMed
34.
Zurück zum Zitat Wolz-Beck M, Reisenauer C, Kolenic GE, Hahn S, Brucker SY, Huebner M (2017) Physiotherapy and behavior therapy for the treatment of overactive bladder syndrome: a prospective cohort study. Arch Gynecol Obstet 295:1211–1217CrossRefPubMed Wolz-Beck M, Reisenauer C, Kolenic GE, Hahn S, Brucker SY, Huebner M (2017) Physiotherapy and behavior therapy for the treatment of overactive bladder syndrome: a prospective cohort study. Arch Gynecol Obstet 295:1211–1217CrossRefPubMed
35.
Zurück zum Zitat Wyman JF, Klutke C, Burgio K, Guan Z, Sun F, Berriman S, Bavendam T (2010) Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Can J Urol 17:5283–5290PubMed Wyman JF, Klutke C, Burgio K, Guan Z, Sun F, Berriman S, Bavendam T (2010) Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Can J Urol 17:5283–5290PubMed
Metadaten
Titel
Überaktive Blase – wann welche Therapie?
verfasst von
Prof. J. Pannek
Publikationsdatum
17.10.2017
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 12/2017
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-017-0522-1

Weitere Artikel der Ausgabe 12/2017

Der Urologe 12/2017 Zur Ausgabe

Mitteilungen der DGU

Mitteilungen der DGU

BDU-Journal – Berufspolitik

BDU-Journal – Berufspolitik

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.